

Disclosures	
Consultant and Research Support	
Inari	
Penumbra	
Imperative Care	
EnVVeno	
Boston Scientific	
WL Gore	
Medtronic	
S Sentara 🕅 🖤 THEOREM AND IN GOINGES	

Background


Mechanical thrombectomy (MT) is a promising treatment option for proximal lower-extremity deep vein thrombosis (DVT)^{1-5}

Long-term outcomes are sparsely reported across the field of DVT intervention6-8

For the first time, we present the ${\bf complete}$ 2-year outcomes of MT with the ClotTriever System and the final primary output of the CLOUT registry


olly, et al. JVSVL 2022. "Weissler, et al. Ann Vasc Surg. 2022. "Dexter, et al. JSCAI. 2023. "Shaikh, et al. CVIR. 2023 isharat, et al. JSCAI. 2024. "Vedantham, et al. NEJM. 2017. "Enden, et al. Lancet. 2012. "Notten, et al. JAHA. 2021.


Sentara Minera Martin Sciences





Complete Outcomes from the Largest Mechanical Thro DVT Design: Prospective, multicenter, all-comer, single-arm registry	
Objective: Evaluate patient outcomes for	N = 499 Patients enrolled from 43 US sites
proximal lower extremity DVT treated with the	
ClotTriever System	n = 340 Status known at 2-vear visit
Primary Endpoint: Complete or near-complete (≥ 75%) thrombus removal by Marder score	· · · · · · · · · · · · · · · · · · ·
Study Conduct:	n = 296
Independent core laboratory assessment of thrombus removal	Alive at 2-year visit
Independent medical monitor adjudication of safety events	Did not complete s
Duplex ultrasound, clinical, and functional outcomes assessed at 2 years	Completed the study


	Characteristic	Median [IQR] or n (%)
9	Age (years)	61.9 [48.0 - 70.8]
⊃atient Level	Female	252 (50.5)
ц	Bilateral DVT	22 (4.4)
atie	Prior history of DVT	124 (24.9)
e,	Contraindicated to thrombolysis	157 (31.5)
P	Provoked DVT	207 (40.3)
ē	Previous treatment of current DVT	120 (23.2)
Limb Level	DVT location	
ę.	Isolated iliofemoral	52 (10.5)
5	lliofemoral and femoral-popliteal	337 (68.1)
	Isolated femoral-popliteal	106 (21.4)











Conclusions

The CLOUT registry demonstrates positive and durable outcomes through 2 years following MT with the ClotTriever System:

Flow and compressibility in over 90% of treated limbs

PTS incidence of 18.5%, with only 6.4% with moderate or severe PTS

Continued improvements in clinical symptoms and quality of life

Definitive evidence to come with the DEFIANCE RCT (NCT05701917):

investigating ClotTriever outcomes compared 1:1 with anticoagulation alone

Sentara ()

Participating Sites		
- ui tieiput		
Principal Investigator	Site Principal Inve	estigator Site
David Dexter (National CoPI)	Sentara Vas Herman Kado	Millennium Cardiology
Robert Beasley (National CoPI).	Mount Sinai Thomas Maldona	Northwell Health
Adam Zybulewski		
Diego Ayo	Advent Heal Eugene Ichinose	Oklahoma Heart
Christopher King	Affinity Card Kaylan Veerina	Opelousas General
Joshua Cockrell	Alabama Cli Sagar Gandhi	Prisma Health Upstate
Jeffery Hnath	Albany Medi Douglas Murrey	Providence Sacred Heart
Abdullah Shaikh	Allegheny H Matthew Bunte	Saint Luke's Hospital of Kansas City
Joseph Paulisin	Ascension C Bhavraj Khalsa	St. Joseph Hospital, Vascular Specialists of OC
Neil Shah	Aurora St. Li Matthew Jung	Surgical Care Associates
Edvard Skripochnik	Columbia Ut Daniel Long	The Christ Hospital
Ezana Azene	Gundersen I Robert Ford	Thomas Jefferson University
David O'Connor	Hackensack Sonya Noor	University of Buffalo
Eric Trestman	Houston His Adam Plotnik	University of California
Ankur Lodha	Lafayette Gr Jonathan Lindquis	
Fakhir Elmasri	Lakeland Va Ambarish Bhat	University of Missouri
Charles Moomey	Longstreet C Manatee Me	University of Texas Health Sciences Center at
James Nguyen		Houston
Nicolas Mouawad	McLaren Ba Vipul Khetarpaul	Washington University
Steven Abramowitz	MedStar Hes Shuo Li	Wesley Medical Center William Beaumont Hospital
Mohannad Bisharat	Memorial Hr Graham Long	Yale University
Adam Raskin	Mercy Healt Hamid Mojibian	
Wesley Angel, Jan Roberts	Methodist Healthcare Foundati	an